AV 513Alternative Names: AV513
Latest Information Update: 08 Mar 2011
At a glance
- Originator Avigen
- Developer Baxter Healthcare Corporation
- Class Antihaemorrhagics; Coagulants; Polysaccharides; Small molecules
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Haemophilia A; Haemophilia B